Here, we set out to characterise BRD9 expression and mutations in depth within 11 independent PCa cohorts to identify whether BRD9 has potential as a biomarker and therapeutic target or co-target in PCa. This evidence concerns the gene BRD9 and posterior cortical atrophy.